Actinium Pharmaceuticals, Inc.
ATNM
$1.26
$0.1614.55%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 90.00K | 90.00K | -- | -- | -- |
| Total Revenue | 90.00K | 90.00K | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 90.00K | 90.00K | -- | -- | -- |
| SG&A Expenses | 15.21M | 15.79M | 17.08M | 18.05M | 12.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.34M | 37.43M | 44.25M | 49.16M | 42.12M |
| Operating Income | -36.25M | -37.34M | -44.25M | -49.16M | -42.12M |
| Income Before Tax | -33.89M | -34.60M | -41.04M | -45.51M | -38.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.89 | -34.60 | -41.04 | -45.51 | -38.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.89M | -34.60M | -41.04M | -45.51M | -38.24M |
| EBIT | -36.25M | -37.34M | -44.25M | -49.16M | -42.12M |
| EBITDA | -35.59M | -36.67M | -43.58M | -48.51M | -41.46M |
| EPS Basic | -1.09 | -1.11 | -1.32 | -1.47 | -1.27 |
| Normalized Basic EPS | -0.68 | -0.69 | -0.82 | -0.92 | -0.80 |
| EPS Diluted | -1.09 | -1.11 | -1.32 | -1.47 | -1.27 |
| Normalized Diluted EPS | -0.68 | -0.69 | -0.82 | -0.92 | -0.80 |
| Average Basic Shares Outstanding | 124.78M | 124.79M | 124.67M | 123.57M | 120.27M |
| Average Diluted Shares Outstanding | 124.78M | 124.79M | 124.67M | 123.57M | 120.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |